Significant New Drug Creation

Keywords:

Product News Download

Shengshi Taikang Opens the Door to Capital Markets, Injecting New Momentum into Innovative Drug Development

Keywords:

Sipu Conference | Dr. Yu Qiang Attends the Healthcare Industry Foresight Forum, Exploring the "Unknown" from the "Known"

Today, the second Health Industry Foresight Forum kicked off in Bo'ao, Hainan, as one of the featured forums at the 2025 West China International Fair. Grounded in the global macro trends of the health industry, the forum closely examined cutting-edge developments and future trajectories in life sciences, providing valuable insights into investment opportunities and R&D directions within the sector. Dr. Yu Qiang, Founder and CEO of Shengshi Taike, was invited to participate in the forum, where he shared his perspectives on breakthroughs and opportunities in pharmaceutical innovation, as well as emerging trends shaping the future of life sciences.

Keywords:

Significant New Drug Creation

Cetagliptin Phosphate

Renowned Experts Gather to Discuss the Ongoing Innovation of DPP-4i Therapies—National Expert Advisory Meeting on Diabetes Treatment Successfully Held under the Theme "Senhu Tang'an: Steadfastly Protecting Pancreatic Health"

On August 22, coinciding with the 22nd Annual Conference of the Chinese Medical Association on Endocrinology (CSE 2025), the "National Expert Advisory Meeting on Diabetes Treatment—Senhutang'an: Upholding Pancreatic Health," organized by the China Medical Education Association, was successfully held. The meeting was co-chaired by Professors Li Yanli from Sun Yat-sen Memorial Hospital of Zhongshan University, Yongquan Shi from Shanghai Changzheng Hospital, Yiming Li from Huashan Hospital Affiliated to Fudan University, and Qing Su from Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. It brought together numerous leading clinical experts from across the country to delve into the innovative mechanisms, evidence-based outcomes, and clinical value of Sengeletin tablets—a next-generation, highly selective dipeptidyl peptidase-4 inhibitor (DPP-4i)—providing valuable guidance and practical insights for optimizing the management of type 2 diabetes mellitus (T2DM).

Keywords:

Significant New Drug Creation

Cetagliptin Phosphate